Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

ADAPT-AB - AI-enabled Edge Data Acquisition and Autonomous Decision-Making Infrastructure for Automated Antibiotic Discovery

Project description

AI-powered solutions for antibiotic discovery

Antibiotics provide a key tool for treating diseases and infections. Unfortunately, as their use increases, so do infections and diseases that become increasingly resistant to antibiotics. Despite key technological advances that enable the automation of experiments crucial to antibiotic discovery and early in vitro toxicology, the largely post hoc, slower biological interpretation of results increases the redundancy of findings. The EIC-funded ADAPT-AB project will develop and validate a perception-and-decision core that will transform script-driven laboratory automation into decision-capable and real-time operation. It will integrate edge AI interpretation, high-frequency sensing, and deterministic decision outputs in experiments to enable safe, autonomous, and faster adaptation under human oversight and defined constraints.

Objective

ADAPT-AB develops and validates a perception-and-decision core that transforms script-driven laboratory automation into real-time, decision-capable operation. Although experiments are automated, biological interpretation remains largely post-hoc, slowing iteration and increasing redundancy in antibiotic discovery and early in-vitro toxicology. ADAPT-AB embeds high-frequency sensing, edge AI interpretation and deterministic decision outputs directly into experiments, enabling safe, autonomous adaptation within predefined constraints and human oversight.
The Physical AI architecture integrates (i) Resistell’s ResiDaq core, enabling multi-channel acquisition up to 60 kHz with embedded preprocessing and AI inference, (ii) FESTO’s LifeTech Controller as deterministic control backbone for robotics and fluid handling, and (iii) nanomotion sensing modules quantifying bacterial and mammalian cellular responses in 96-well formats. ResiDaq fuses efficacy and toxicity outputs and issues unified commands to the LifeTech Controller to orchestrate liquid handling, incubation and connected devices in a closed loop.
Resistell, the applicant, provides the ResiDaq edge AI platform, proprietary nanomotion technology, certified BSL2 laboratories and an ISO 13485-compliant QMS, supported by granted and pending patents covering sensing, optical readout and signal analysis algorithms. FESTO contributes industrial automation expertise and its LifeTech platform, enabling scalable integration and deployment.
Stage 1 delivers a TRL 6 integrated prototype validated under realistic laboratory conditions and benchmarked against growth-based and endpoint assays using predefined KPIs. Commercialisation follows a dual path: ResiDaq as an OEM-ready embeddable decision layer for third-party automation, and the fully integrated closed-loop platform for antibiotic and toxicology workflows, enabling scale-up through OEM partnerships, licensing and industrial deployment in Stage 2 and beyond.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2026-AIC

See all projects funded under this call

Coordinator

RESISTELL AG
Net EU contribution
€ 300 000,00
Address
HOFACKERSTRASSE 40B
4132 Muttenz
Switzerland
SME
Yes
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Landschaft
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data